KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Accumulated Expenses (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Other Accumulated Expenses for 13 consecutive years, with $26.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses changed N/A to $26.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $26.3 million, a N/A change, with the full-year FY2023 number at $4.3 million, down 74.6% from a year prior.
  • Other Accumulated Expenses was $26.3 million for Q3 2025 at Supernus Pharmaceuticals, up from $3.6 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $26.3 million in Q3 2025 to a low of $710000.0 in Q3 2023.
  • A 5-year average of $12.0 million and a median of $10.6 million in 2022 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: skyrocketed 121.67% in 2021, then crashed 74.6% in 2023.
  • Supernus Pharmaceuticals' Other Accumulated Expenses stood at $20.1 million in 2021, then dropped by 16.24% to $16.9 million in 2022, then plummeted by 74.6% to $4.3 million in 2023, then dropped by 15.41% to $3.6 million in 2024, then skyrocketed by 626.52% to $26.3 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Other Accumulated Expenses are $26.3 million (Q3 2025), $3.6 million (Q2 2024), and $4.3 million (Q4 2023).